Biodexa rises on FDA's 'fast track' tag for rare disease drug
10/02/2025 16:43
** U.S.-listed shares of UK-based drugmaker Biodexa's
5MP1y.F BDRX.O rise 57% to $6.50
** Company says U.S. FDA has granted fast track designation
to its experimental drug eRapa, which is the oral tablet
formulation of the drug rapamycin
** eRapa is being developed for the treatment of familial
adenomatous polyposis, a rare, inherited condition that causes
extra tissue or polyps to form in the large intestine and rectum
** The FDA's "Fast Track" program is designed to facilitate
the development and expedite the review of drug candidates to
treat serious conditions and fill an unmet medical need
** Stock fell 80.2% in 2024
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))